Islet Function and Dysfunction in Diabetes Mellitus and Transplantation
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 2695
Special Issue Editor
2. Renal and Transplant Unit, Westmead Hospital, Westmead, NSW 2145, Australia
3. Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
Interests: kidney; acute kidney injury; chronic kidney disease; angiogenesis; signal transduction; dendritic cell biology; transplantation; islet biology
Special Issue Information
Dear Colleagues,
Diabetes mellitus is the third most common chronic condition experienced worldwide, after cancer and cardiovascular disease. Absent or defective insulin secretion are pathological features of type 1 and type 2 diabetes mellitus (DM). The immunological destruction of islets is a pathognomonic feature of type 1 DM, and is typically preceded by autoantibody production. Multiple endocrine pancreas abnormalities are seen in type 2 patients, ranging from changes in beta cell mass to exhaustion and loss. The manifestation of DM is often associated with altered genetic signaling.
Since the discovery and isolation of insulin in 1921, this has been the mainstay of diabetic treatment, although its exogenous administration cannot mimic normal metabolic control. Islet transplantation is a promising therapeutic option for type 1 diabetics. However, widespread application and long-term success is limited. The reality of the current transplant technique is challenging—more than 50% of islets are destroyed in the initial post-transplant period, multiple stress responses (hypoxia, inflammation, lack of angiogenesis) diminish islet function, and the immunosuppression required is itself diabetogenic.
This Special Issue will focus on derangements in islet cell biology in diabetes and following islet transplantation.
Dr. Natasha M. Rogers
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- type 1 diabetes mellitus
- type 2 diabetes mellitus
- islet transplantation
- islet dysfunction
- insulin
